Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

Psoriasis News

the latest news from ipc, industry and others

IPC

Displaying 1 to 10 of 95 Posts . Displaying 10 of Posts . Page of 10 . Go To Page: . Per Page: . . . View All Sort By: .

WHO report on psoriasis

Milestone WHO report raises awareness of psoriasis as a serious global disease

Read More

Classifying Disease Severity

Dr. Strober details the IPC Psoriasis Disease Severity Reclassification project, which advocates for a revised severity scoring system to improve psoriasis patient access.

Read More

WHO Academy COVID-19 mobile app

The WHO Academy’s mobile learning app has been designed specifically for health workers and is now available to download.

Read More

Commentary: Dermatologists and SARS - CoV - 2: the impact of the pandemic on daily practice

Paolo Gisondi et al., summarize issues faced by many dermatologists during the unprecedented lockdown period in Spring 2020 due to the COVID-19 pandemic. Issues like the sudden cancellation of face-to-face consultations, and the mandatory introduction of telemedicine (after months of a rather optional exercise with this type of caregiving), needed an entrepreneurial approach to manage.

Read More

Lilly's Mirikizumab Superior to Cosentyx® (secukinumab) in a Phase 3 Study for Patients with Moderate to Severe Plaque Psoriasis

Eli Lilly and Company (NYSE:LLY) announced today that mirikizumab, an investigational monoclonal antibody that binds to the p19-subunit of IL23, met the primary and all key secondary endpoints versus placebo at Week 16 (superiority) and all key secondary endpoints versus Cosentyx (secukinumab) at Week 16 (non-inferiority) and Week 52 (superiority) in the OASIS-2 study. OASIS-2 is a multicenter randomized, double-blind, placebo-controlled study comparing the efficacy and safety of mirikizumab to placebo and Cosentyx in patients with moderate to severe plaque psoriasis.

Read More

Pathogenesis of Psoriasis

Dr. Stingl discusses differences in the pathogenesis of plaque psoriasis and pustular psoriasis. Spoiler alert: it's the neutrophils.

Read More

2021 IPC Events Calendar

IPC is already planning for the future with multiple events scheduled for the upcoming year.

Read More

PsoProtectMe now available in multiple languages

PsoProtectMe now available in multiple languages

Read More

IPC Webinar | COVID-19 y psoriasis: Informes ibero-latinoamericanos del IPC

IPC Webinar | COVID-19 y psoriasis: Informes ibero-latinoamericanos del IPC

Read More

Optimizing the Use of Biologics

Dr. Armstrong guides us through the process of choosing which biologic to use as a psoriasis treatment.

Read More
now available

COVID-19 Psoriasis Resource Center

Information from around the world on psoriasis and coronavirus to assist dermatologists and the patients they serve

explore now

Stay informed

Join the email list to receive the latest information on psoriasis meetings, manuscripts and research.
SUBSCRIBE

Search Our Blog

  Search
 

We use cookies on this site to enhance your online experience. By continuing to use this site, you agree to accept cookies.
OK